Bupivacaine as pre-emptive analgesia in third molar surgery: Randomised controlled trial.
We conducted a prospective, randomised study on the use of pre-emptive analgesia in 45 patients who had bilateral impacted third molars removed. Bupivacaine 0.5% with adrenaline 1:200,000 was injected on one side, the other side acting as control. A visual analogue scale was used to measure the extent of postoperative pain. There was a significant reduction (p = 0.05) in postoperative pain on the injected side at 6, 12, and 72 h and an overall reduction in pain up to 7 days.
Nayyar
M Sharif
MS
National Maxillofacial Unit, Registrar Maxillofacial Unit, St James Hospital, Dublin 8, Republic of Ireland. sharifnayyar@hotmail.com
Yates
C
C
D000293:Adolescent; D000328:Adult; D000766:Anesthesia, Dental; D000779:Anesthetics, Local / Q000008:administration & dosage*; D002045:Bupivacaine / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006987:Hypesthesia / Q000139:chemically induced; D008036:Lingual Nerve / Q000187:drug effects; D008046:Lip / Q000294:innervation; D008297:Male; D008340:Mandibular Nerve / Q000187:drug effects; D008964:Molar, Third / Q000601:surgery*; D009407:Nerve Block; D010147:Pain Measurement; D010149:Postoperative Pain / Q000517:prevention & control*; D011183:Postoperative Complications; D011446:Prospective Studies; D014081:Tooth Extraction; D014095:Tooth, Impacted / Q000601:surgery
D000779:Anesthetics, Local; D002045:Bupivacaine